Pancreatic Adenocarcinoma, Version 2.2014

Pancreatic Adenocarcinoma, Version 2.2012

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regardi...

Pancreatic Adenocarcinoma NCCN Pancreatic Adenocarcinoma Panel Members

Exocrine pancreatic adenocarcinoma in a toy breed dog

A 4-year-old female miniature pincher with a 40-day history of weight loss, lethargy and vomiting was referred to Small Animal Hospital, Faculty of Veterinary Medicine, University of Tehran. The case also had severe jaundice, chronic diarrhoea and steatorrhoea. The efforts for saving the life of the case were not successful and finally the animal died of hypovolaemic shock and electrolyte imbal...

Pancreatic adenocarcinoma in a patient with relapsed Hodgkin’s lymphoma

After curative treatment of Hodgkin’s lymphoma, increased risk of certain solid tumors has been reported. To best of our knowledge this is the first report of metachronous pancreatic adenocarcinoma which developed outside the previous radiation field in a patient with relapse Hodgkin’s lymphoma. Herein we present an 81-year-old female who developed pancreatic adenocarcinoma four yea...

Chemotherapy in pancreatic adenocarcinoma.

Pancreatic cancer is a malignancy with a very poor prognosis, even when radically resected. In advanced disease chemotherapy has a role in terms of clinical benefit and symptoms palliation, more than survival advantage. Gemcitabine as a single agent is the first-line standard treatment since 1997. Several trials failed to demonstrate a survival advantage of chemotherapy doublets or gemcitabine ...